8-K: Leap Therapeutics Announces Promising Clinical Data for DKN-01 in Colorectal Cancer

Leap Therapeutics reports positive results from its DeFianCe study, showing DKN-01 in combination with standard therapy demonstrates encouraging efficacy in second-line colorectal cancer patients, particularly those with left-sided tumors.

Summary

• Leap Therapeutics has released new clinical data from Part A of the DeFianCe study, which evaluates DKN-01 in combination with bevacizumab and chemotherapy for second-line colorectal cancer.
• The study showed an overall response rate (ORR) of 30% and a disease control rate (DCR) of 93% across all evaluable patients.
• A subgroup analysis revealed a 46% ORR and 100% DCR in patients with rectal and rectosigmoid tumors, with a preliminary median progression-free survival (PFS) of 9.4 months.
• The treatment was generally well-tolerated, with most DKN-01 related events being low grade.
• Part B of the study, a randomized controlled trial, is underway with 54 patients currently enrolled and is expected to complete enrollment mid-year.

Sentiment

Score: 8

Explanation: The document presents positive clinical data with strong efficacy signals, particularly in a specific subgroup, and a favorable safety profile. The company is moving forward with a randomized controlled trial, indicating confidence in the treatment. The sentiment is very positive.

Positives

• The study demonstrated clinically meaningful response rates and durable tumor reductions with a favorable safety profile.
• The combination therapy showed enhanced activity in left-sided tumors, particularly rectal and rectosigmoid tumors.
• Higher baseline plasma DKK1 levels correlated with improved responses.
• The results provide a strong foundation for the randomized controlled Part B of the study.
• The study is enrolling well and is expected to complete enrollment mid-year.

Negatives

• The study is still in Phase 2, and further data is needed to confirm these results.
• The median PFS for the overall population was 6.3 months, which is lower than the subgroup with rectal/rectosigmoid carcinomas.

Risks

• The success of the clinical trials and the timing of enrollment are subject to risks.
• The results of clinical trials and pre-clinical studies may not be as expected.
• There is a risk that the company may not be able to successfully enter into new strategic partnerships.
• Regulatory approval from the FDA or equivalent foreign agencies is not guaranteed.
• The company is exposed to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of its traded securities.
• Global conflict or supply chain issues may delay or adversely affect clinical trials.

Future Outlook

The company anticipates completing enrollment for Part B of the DeFianCe study mid-year and will continue to develop DKN-01 in various cancer types.

Management Comments

• Meredith Pelster, MD, stated that the addition of DKN-01 to bevacizumab and chemotherapy can generate clinically meaningful response rates and durable tumor reductions with a favorable safety profile.
• Zev Wainberg, MD, noted that the results represent an encouraging efficacy signal, particularly in left-sided and rectal tumors.
• Management believes that DKN-01 can modulate the Wnt pathway and overcome resistance to chemotherapy.

Industry Context

The announcement is significant in the context of colorectal cancer treatment, where there is a need for more effective second-line therapies, particularly for patients with left-sided tumors. The results suggest that DKN-01 could be a valuable addition to the treatment landscape.

Comparison to Industry Standards

• The 30% ORR in the overall population is comparable to other second-line treatments for colorectal cancer, but the 46% ORR in the rectal/rectosigmoid subgroup is notably higher.
• The 93% DCR is also a strong result, indicating that the treatment is effective in controlling the disease in a large proportion of patients.
• The preliminary median PFS of 9.4 months in the rectal/rectosigmoid subgroup is competitive with other targeted therapies in this setting.
• Companies like Amgen with Vectibix and Eli Lilly with Cyramza are competitors in the colorectal cancer space, and the results of the DeFianCe study will be closely watched to see how DKN-01 compares.

Stakeholder Impact

• Shareholders will likely react positively to the encouraging clinical data.
• Patients with colorectal cancer may benefit from this new treatment option.
• The company's employees may be motivated by the positive results.
• The company's partners may be more interested in collaborating on future projects.

Next Steps

• The company will continue to enroll patients in Part B of the DeFianCe study.
• Leap will host a conference call on January 23, 2024, to further discuss the data.
• The company will present the data at the 2024 ASCO Gastrointestinal Cancers Symposium.

Key Dates

Keywords

DKN-01, colorectal cancer, CRC, DeFianCe study, bevacizumab, chemotherapy, oncology, clinical trial, Phase 2, ORR, PFS, DCR, left-sided tumors, rectal cancer, biotechnology